CLAIMS

1. Use of a substance including an RNA pathogen mimic with a delivery agent comprising polyethylenimine (PEI), in the manufacture of a medicament for the treatment of a tumor of a patient, wherein the administration pattern of the medicament comprises a therapeutically effective amount of the substance to be administered to the patient, in one or more sessions, before the tumor is to be treated with intra-tumoral alpha-emitter radiotherapy, and where the intra-tumoral alpha-emitter radiotherapy is to be performed less than two weeks after the substance is to be administered, and at least 12 hours after a last dose of the substance is to be administered.

2. The use of claim 1, wherein the substance comprises polyIC with polyethylenimine (PEI).

3. The use of claim 1, wherein the substance comprises poly-ICLC.

4. The use of claim 1, wherein the substance comprises an oncolytic virus.

5. The use of claim 1, wherein the substance comprises BO-112.

6. The use of any one of claims 1-5, wherein the administration pattern of the medicament further comprises a supportive treatment drug to be administered for checkpoint inhibition.

7. The use of claim 6, wherein the supportive treatment drug comprises a checkpoint blockade.

8. The use of any one of claims 1-7, wherein the intra-tumoral alpha-emitter radiotherapy is provided by a source carrying radium atoms.

9. The use of any one of claims 1-8, wherein the intra-tumoral alpha-emitter radiotherapy is provided by a source carrying alpha-emitting atoms mounted on the source in a manner which allows controllable release of the alpha-emitting atoms or their daughter radionuclides from the source.